Burlington, Massachusetts — December 24, 2025 — Leads & Copy — PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), has appointed Jeffrey R. Williams as Independent Director, the company announced today.
“We are pleased to welcome Jeffrey to our Board of Directors for PharmaEssentia USA,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer. “Jeffrey’s global governance and financial acumen, along with his deep understanding of the East Asian market, will be instrumental as we continue to strengthen our international footprint and deliver innovation to patients worldwide.”
Mr. Williams has decades of experience in global finance, governance, and philanthropy, with a career deeply rooted in East Asia. He has served as an Independent Director of PharmaEssentia Corporation in Taiwan since May 2024. He currently serves as Director of UBS SDIC Fund Management Company, UBS Asset Management (China), and Koo Foundation Cancer Center Hospital. He is also a Trustee of the CMB Foundation, a trustee of Carleton-Willard Homes, and a Council Member of the Asian Corporate Governance Association.
Mr. Williams earned both his A.B. in East Asian Languages and Civilizations and his M.B.A. from Harvard University.
“Having had the opportunity to work closely with PharmaEssentia’s leadership team in Taiwan, I’ve seen firsthand the company’s dedication to scientific excellence and patient impact,” said Mr. Williams. “I’m honored to now extend that partnership to the USA Corporation and look forward to helping guide the company’s continued expansion as it brings innovative therapies to patients around the world.”
PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Founded in 2003, PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a biologics production facility in Taichung, Taiwan.
Source: PharmaEssentia
